Energy levels, the ability to concentrate on everyday activities, and the ability to exercise are the 3 aspects of a patient’s life that are most affected by immune thrombocytopenia (ITP) in Iran, according to responses from the ITP World Impact Survey (I-WISh). 

The management and perception of the impact of the disease on the life of patients seem to align well between adult and pediatric patients and between adult and pediatric hematologists, according to the results of the survey. 

Read more about the treatment of ITP

The study was published online in the journal Clinical and Applied Thrombosis/Hemostasis.

Moreover, most symptoms seem to be generally well managed, and physicians seem to have experience in managing patients with ITP and a good understanding of the benefits and limitations of the treatments that are currently available in Iran, the study authors noted.

Information about the perspective of patients and physicians alike in terms of the management of ITP as well as its impact on patients’ lives is limited in Iran.

To tackle this problem, a team of researchers, led by Mohammad Faranoush, MD, from the Iran University of Medical Sciences in Tehran, conducted the I-WISh in Iran between October 2019 and October 2020.

A total of 114 patients and 47 physicians were included in the survey. Of these 114 patients, 17 were children under 17 years of age and of the physicians, 22 were pediatric hematologists while the rest were adult hematologists. 

Frequently reported symptoms by patients at the time of diagnosis and at the completion of the survey included fatigue and anxiety. 

Physicians’ preferred method of treatment was “watch-and-wait” after the first diagnosis while the treatment that they prescribed the most to newly diagnosed patients was steroids.

Nearly half (40%) of adult hematologists and 38% of pediatric hematologists said that ITP reduced the quality of life of their patients. 

“In conclusion, this local I-WISh survey underlined the extent to which ITP negatively impacted patients’ life in Iran, in line with the global findings,” the researchers wrote. “We hope that the present study may assist physicians in optimizing the clinical and emotional management of patients with ITP in Iran.”

ITP is a rare bleeding disorder characterized by very low levels of platelet counts caused by the autoantibodies that attack the proteins of the platelet membrane. The disease can have a negative impact on many aspects of a patient’s life. 

Reference

Eshghi P, Abolghasemi H, Akhlaghi AA, et al. Patient and physician perspectives in the management of immune thrombocytopenia in Iran: responses from the ITP World Impact Survey (I-WISh). Clin. Appl. Thromb./Hemost. Published online January 11, 2023. doi:10.1177/10760296221130335